Add BrightSurf on Google Email

Science News for June 26, 2010


Once-weekly exenatide injection improves blood sugar control more than daily oral sitagliptin or pioglitazone and induces more weight loss (DURATION-2 study)

The DURATION-2 study found that once-weekly exenatide improved HbA1c levels by 1.5% compared to 0.9% for sitagliptin and 1.2% for pioglitazone, with significant weight loss in the exenatide group. The findings suggest that exenatide should be considered as an adjunct to metformin for improving glucose control and weight loss.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJun 26, 2010